Loading clinical trials...
Loading clinical trials...
A Phase 3, Double-Blind, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension
Conditions
Interventions
azilsartan
Olmesartan medoxomil
Locations
1
China
Beijing ANZHEN Hospital
Beijing, China
Start Date
January 1, 2015
Primary Completion Date
October 1, 2015
Last Updated
April 2, 2015
NCT06823947
NCT06604897
NCT07448506
NCT07433790
NCT07421388
NCT07421401
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions